JAGDISH PRASAD MEENA

Dr. JAGDISH PRASAD MEENA

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
JMJAGDISH PRASAD MEENA
JAGDISH PRASAD MEENA
Aditya K GuptaAditya K Gupta
Aditya K Gupta
PTPranay Tanwar
Pranay Tanwar
KJKana Ram Jat
Kana Ram Jat
RPRavindra Mohan Pandey
Ravindra Mohan Pandey
RSRachna Seth
Rachna Seth

1 January 2016 in Journal of Pediatric Neurosciences
Verified
Journal Article
Open access
PDF file
JMJAGDISH PRASAD MEENA
JAGDISH PRASAD MEENA
RSRachna Seth
Rachna Seth
BCBiswaroop Chakrabarty
Biswaroop Chakrabarty
SGSheffali Gulati
Sheffali Gulati
SASandeep Agrawala
Sandeep Agrawala
PNPriyanka Naranje
Priyanka Naranje
The opsoclonus-myoclonus ataxia syndrome (OMAS) also called “Kinsbourne syndrome” or “dancing eye syndrome” is a rare but serious disorder characterized by opsoclonus, myoclonus, and ataxia, along with extreme irritability and behavioural changes. Data on its epidemiology, clinical features, and outcome are limited worldwide. The aim of the study was to evaluate the clinical profile and outcome of children with OMAS. A retrospective data of all children presented to Pediatric oncology clinic with a diagnosis of opsoclonus-myoclonus from 2013 to 2016 were collected. 6 patients with a diagnosis of OMAS were presented over a 4-year period. All 6 cases had paraneoplastic etiology. All Children had good outcome without any relapse. Paraneoplastic opsoclonus myoclonus had a good outcome in our experience.

1 January 2021
Verified
Closed access
AGAditya Kumar Gupta
Aditya Kumar Gupta
JMJAGDISH PRASAD MEENA
JAGDISH PRASAD MEENA
ACAnita Chopra
Anita Chopra
PTPranay Tanwar
Pranay Tanwar
RSRachna Seth
Rachna Seth

10 July 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SPSatya Prakash
Satya Prakash
JMJAGDISH PRASAD MEENA
JAGDISH PRASAD MEENA
Aditya K GuptaAditya K Gupta
Aditya K Gupta
SBSameer Bakhshi
Sameer Bakhshi
TVThirumurthy Velpandian
Thirumurthy Velpandian
RSRachna Seth
Rachna Seth

9 May 2023 in Endocrine Pathology
Verified
Journal Article
Closed access
PDF file
HJHemlata Jangir
Hemlata Jangir
IAIsheeta Ahuja
Isheeta Ahuja
Shipra AgarwalShipra Agarwal
Shipra Agarwal
VJVishesh Jain
Vishesh Jain
JMJAGDISH PRASAD MEENA
JAGDISH PRASAD MEENA
KMKalaivani Mani
Kalaivani Mani

17 March 2023 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
PGPriyanka Gupta
Priyanka Gupta
KBKiran Kumar Dm Banothu
Kiran Kumar Dm Banothu
PHPartha Haldar
Partha Haldar
AGAditya Kumar Gupta
Aditya Kumar Gupta
JMJAGDISH PRASAD MEENA
JAGDISH PRASAD MEENA
The outcomes of pediatric chronic myeloid leukemia (CML) have improved with the use of imatinib mesylate (IM). Multiple reports of growth deceleration with IM have raised concerns, necessitating careful monitoring and evaluation in children with CML. We systematically searched the databases of PubMed, EMBASE, Scopus, CENTRAL, and conferences-abstracts, reporting the effect of IM on growth among children with CML, and published in the English language from inception till March 2022. For observational studies, the modified Newcastle Ottawa Scale was used to assess the risk of bias. Pooled estimates were derived using a random-effects meta-analysis, and heterogeneity was assessed using Cochrane Q statistic test of heterogeneity and I 2 statistic. Of the 757 studies identified through electronic search, 15 (n=265) were included in the final analysis. Six studies (n=178) were included in the meta-analysis of the primary outcome. There was a significant deleterious effect of IM on height—standardized mean difference (SMD): −0.52 (95% CI: −0.76; −0.28) (I 2=13%). The adverse effect of IM on height was significant among studies with a follow-up period <3 years [SMD: −0.66 (95% CI: −0.93, −0.40), I 2=0%, P=0.59] but not in studies with follow-up period ≥3 years [SMD: −0.26 (95% CI: −0.63, 0.11), I 2=0, P=0.44], indicating that the effect of IM on height is a short-term effect. The effect of IM on height was not dependent upon pubertal status at the initiation of therapy. Prospective studies with adequate sample size are required to confirm the findings of the effect of IM on height in children with CML.